News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Biotechnology Industry Organization (BIO) Urges Senate Committee on Finance Not to Limit Patients’ Access to Therapies
April 13, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) opposes the Chairman’s Mark to the Medicare Prescription Drug Price Negotiation Act of 2007 (S. 3) which is being considered by the Senate Committee on Finance today.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Government
Chaos at CDC Continues as Hundreds Fired, Rehired
October 13, 2025
·
2 min read
·
Tristan Manalac
BIOSECURE Act
The BIOSECURE Act Is Back, as Congress Tacks New Version On to Broader Defense Bill
October 10, 2025
·
1 min read
·
Annalee Armstrong
Policy
NHS Mulls Greater Pharma Spending to Head Off Trump’s Tariffs: Report
October 10, 2025
·
2 min read
·
Tristan Manalac
Vaccines
ACIP Meeting Delayed Indefinitely; COVID-19 Vaccines Continue To Show Benefit in New Study
October 9, 2025
·
2 min read
·
Tristan Manalac